Please assess the completion status of the following clinical trial:

Trial Title: Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of hormone receptor (HR)-negative, human epidermal growth factor receptor 2 (HER2)-negative (locally recurrent or metastatic TNBC) breast cancer~* Available TNBC diagnostic tumor tissue (archived tissue allowed)~* Evaluable disease~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1~* Adequate organ function~* Predicted life expectancy of 3 or more months~Exclusion Criteria:~* More than 2 prior chemotherapy regimens for locally recurrent or metastatic TNBC. If \> 12 months have elapsed between the date of last adjuvant/neoadjuvant chemotherapy administration and first documented local or distant disease recurrence the therapy will not be considered a line of therapy in the locally recurrent or metastatic TNBC setting.~* CNS metastases or leptomeningeal disease requiring immediate treatment with radiation therapy or steroids.~* Investigational drug within 30 days of first trilaciclib (G1T28) dose~* Concurrent radiotherapy, radiotherapy within 14 days of first trilaciclib (G1T28) dose~* Cytotoxic chemotherapy within 3 weeks of first trilaciclib (G1T28) dose~* Prior hematopoietic stem cell or bone marrow transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Gemcitabine/Carboplatin (Days 1 and 8) (Type: EXPERIMENTAL): Participants received Intravenous (IV) infusion of standard GC chemotherapy (gemcitabine 1000 milligrams per meter square \[mg/m\^2\] and carboplatin area under the curve \[AUC\] 2) on Days 1 and 8 of 21-day cycle. The carboplatin dose was calculated using the Calvert formula, with a target AUC 2 (maximum 300 mg).
- Group 2: Trilaciclib + Gemcitabine/ Carboplatin (Days 1 and 8) (Type: EXPERIMENTAL): Participants received IV infusion of trilaciclib 240 mg/m\^2 plus GC chemotherapy (gemcitabine 1000 mg/m\^2 and carboplatin AUC 2) IV infusion on Days 1 and 8 of 21-day cycle. Trilaciclib was administered prior to chemotherapy.
- Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) (Type: EXPERIMENTAL): Participants received IV infusion of trilaciclib 240 mg/m\^2 on Days 1, 2, 8, and 9 plus GC chemotherapy (gemcitabine 1000 mg/m\^2 and carboplatin AUC 2) IV infusion on Day 2 and 9 of 21-day Cycle. Trilaciclib was administered prior to chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).